These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12841940)

  • 21. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.
    Marsà Carretero M; Alos Manrique C; Valles Callol JA
    Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671
    [No Abstract]   [Full Text] [Related]  

  • 22. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis.
    Andreou ER; Ledger S
    Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscular adverse effects of statins.
    Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
    [No Abstract]   [Full Text] [Related]  

  • 25. [Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].
    SantaCruz PL; González A; León ME; Fernández MY
    Nefrologia; 2002; 22(3):301-2. PubMed ID: 12123135
    [No Abstract]   [Full Text] [Related]  

  • 26. The withdrawal of Baycol (cerivastatin).
    Griffin JP
    Adverse Drug React Toxicol Rev; 2001 Dec; 20(4):177-80. PubMed ID: 11770168
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mechanisms of rhabdomyolysis with statins].
    Magalhães ME
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():42-4. PubMed ID: 16400398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
    Yang KC; Fang CC; Su TC; Lee YT
    Am J Kidney Dis; 2005 Mar; 45(3):e57-60. PubMed ID: 15754265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin.
    Schindler C; Thorns M; Matschke K; Tugtekin SM; Kirch W
    Clin Ther; 2007 Jan; 29(1):172-6. PubMed ID: 17379057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin: renal disorders and rhabdomyolysis.
    Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rhabdomyolysis as a side effect of simvastatin treatment].
    Iskra B; Zivko M; Kes P
    Acta Med Croatica; 2005; 59(4):325-8. PubMed ID: 16334740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual hepatic metabolism of cerivastatin--clarifications.
    Guyton JR; Dujovne CA; Illingworth DR
    Am J Cardiol; 1999 Aug; 84(4):497. PubMed ID: 10468102
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Statins in patients with renal failure--the current therapeutic status].
    Filipiak KJ; Zawadzka-Byśko M
    Przegl Lek; 2005; 62 Suppl 2():51-4. PubMed ID: 16623120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
    Kubota T; Fujisaki K; Itoh Y; Yano T; Sendo T; Oishi R
    Biochem Pharmacol; 2004 Jun; 67(12):2175-86. PubMed ID: 15163549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayer pulls cerivastatin (Baycol) from market.
    Wooltorton E
    CMAJ; 2001 Sep; 165(5):632. PubMed ID: 11563216
    [No Abstract]   [Full Text] [Related]  

  • 39. [Undesirable drug interactions of hypolipemic drugs].
    Chojnowska-Jezierska J
    Pol Merkur Lekarski; 2000 Sep; 9(51):618-20. PubMed ID: 11126989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.